307 related articles for article (PubMed ID: 31686616)
1. Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience.
Botticella A; Mezquita L; Le Pechoux C; Planchard D
Ther Adv Respir Dis; 2019; 13():1753466619885530. PubMed ID: 31686616
[TBL] [Abstract][Full Text] [Related]
2. Durvalumab for the treatment of non-small cell lung cancer.
Murakami S
Expert Rev Anticancer Ther; 2019 Dec; 19(12):1009-1016. PubMed ID: 31782989
[No Abstract] [Full Text] [Related]
3. Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
Melosky B; Juergens R; McLeod D; Leighl N; Brade A; Card PB; Chu Q
Lung Cancer; 2019 Aug; 134():259-267. PubMed ID: 31319991
[TBL] [Abstract][Full Text] [Related]
4. Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer.
Shaverdian N; Offin MD; Rimner A; Shepherd AF; Wu AJ; Rudin CM; Hellmann MD; Chaft JE; Gomez DR
Radiother Oncol; 2020 Mar; 144():101-104. PubMed ID: 31786421
[TBL] [Abstract][Full Text] [Related]
5. Safety evaluation of durvalumab for the treatment of non-small-cell lung cancer.
Shibata Y; Murakami S
Expert Opin Drug Saf; 2020 Jun; 19(6):653-659. PubMed ID: 32357806
[TBL] [Abstract][Full Text] [Related]
6. DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy.
Filippi AR; Dziadziuszko R; García Campelo MR; Paoli JB; Sawyer W; Díaz Pérez IE
Future Oncol; 2021 Dec; 17(34):4657-4663. PubMed ID: 34775804
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.
Criss SD; Mooradian MJ; Sheehan DF; Zubiri L; Lumish MA; Gainor JF; Reynolds KL; Kong CY
JAMA Oncol; 2019 Mar; 5(3):358-365. PubMed ID: 30543349
[TBL] [Abstract][Full Text] [Related]
8. Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial.
Bozorgmehr F; Chung I; Christopoulos P; Krisam J; Schneider MA; Brückner L; Mueller DW; Thomas M; Rieken S
BMC Cancer; 2020 Aug; 20(1):806. PubMed ID: 32842974
[TBL] [Abstract][Full Text] [Related]
9. Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria.
Sakaguchi T; Ito K; Furuhashi K; Nakamura Y; Suzuki Y; Nishii Y; Taguchi O; Hataji O
Respir Investig; 2019 Sep; 57(5):466-471. PubMed ID: 31104989
[TBL] [Abstract][Full Text] [Related]
10. Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC).
Socinski MA; Özgüroğlu M; Villegas A; Daniel D; Vicente D; Murakami S; Hui R; Gray JE; Park K; Vincent M; Mann H; Newton M; Dennis PA; Antonia SJ
Clin Lung Cancer; 2021 Nov; 22(6):549-561. PubMed ID: 34294595
[TBL] [Abstract][Full Text] [Related]
11. Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer.
Riudavets M; Auclin E; Mosteiro M; Dempsey N; Majem M; Prelaj A; López-Castro R; Bosch-Barrera J; Pilotto S; Escalera E; Tagliamento M; Mosquera J; Zalcman G; Aboubakar Nana F; Ponce S; Albarrán-Artahona V; Dal Maso A; Spotti M; Mielgo X; Mussat E; Reyes R; Benítez JC; Lupinacci L; Duchemann B; De Giglio A; Blaquier JB; Audigier-Valette C; Scheffler M; Nadal E; Lopes G; Signorelli D; Garcia-Campelo R; Menis J; Bluthgen V; Campayo M; Recondo G; Besse B; Mezquita L; Planchard D
Clin Lung Cancer; 2024 May; 25(3):233-243.e8. PubMed ID: 38105153
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer: focus on treatment selection and prognostic factors.
Guberina M; Guberina N; Pöttgen C; Gauler T; Richlitzki C; Metzenmacher M; Wiesweg M; Plönes T; Forsting M; Wetter A; Herrmann K; Hautzel H; Darwiche K; Theegarten D; Aigner C; Schuler M; Stuschke M; Eberhardt WE
Immunotherapy; 2022 Aug; 14(12):927-944. PubMed ID: 35822656
[TBL] [Abstract][Full Text] [Related]
13. A new standard of care for patients with surgically unresectable stage III non-small cell lung cancer.
Gill HS; Ramalingam SS
Cancer; 2019 Jul; 125(13):2148-2153. PubMed ID: 30825394
[No Abstract] [Full Text] [Related]
14. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
Antonia SJ; Villegas A; Daniel D; Vicente D; Murakami S; Hui R; Kurata T; Chiappori A; Lee KH; de Wit M; Cho BC; Bourhaba M; Quantin X; Tokito T; Mekhail T; Planchard D; Kim YC; Karapetis CS; Hiret S; Ostoros G; Kubota K; Gray JE; Paz-Ares L; de Castro Carpeño J; Faivre-Finn C; Reck M; Vansteenkiste J; Spigel DR; Wadsworth C; Melillo G; Taboada M; Dennis PA; Özgüroğlu M;
N Engl J Med; 2018 Dec; 379(24):2342-2350. PubMed ID: 30280658
[TBL] [Abstract][Full Text] [Related]
15. Long-term response with durvalumab after chemoradiotherapy for pulmonary pleomorphic carcinoma: A case report.
Yorozuya T; Taya T; Yasuda K; Nagano Y; Shioya M; Chiba H; Takahashi H
Thorac Cancer; 2020 Apr; 11(4):1090-1093. PubMed ID: 32045109
[TBL] [Abstract][Full Text] [Related]
16. Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancer.
Chu CH; Chiu TH; Wang CC; Chang WC; Huang AC; Liu CY; Wang CL; Ko HW; Chung FT; Hsu PC; Guo YK; Kuo CS; Yang CT
Thorac Cancer; 2020 Jun; 11(6):1541-1549. PubMed ID: 32281272
[TBL] [Abstract][Full Text] [Related]
17. The changing landscape of stage III lung cancer: a literature review.
Patel M; Bruno D; Grubb W; Biswas T
Expert Rev Anticancer Ther; 2020 Aug; 20(8):675-686. PubMed ID: 32667262
[TBL] [Abstract][Full Text] [Related]
18. MEDI 4736 (durvalumab) in non-small cell lung cancer.
Jeanson A; Barlesi F
Expert Opin Biol Ther; 2017 Oct; 17(10):1317-1323. PubMed ID: 28705024
[TBL] [Abstract][Full Text] [Related]
19. Real-World Incidence of Pneumonitis in Patients Receiving Durvalumab.
LeClair JN; Merl MY; Cohenuram M; Luon D
Clin Lung Cancer; 2022 Jan; 23(1):34-42. PubMed ID: 34556401
[TBL] [Abstract][Full Text] [Related]
20. Durvalumab in non-small-cell lung cancer patients: current developments.
Mezquita L; Planchard D
Future Oncol; 2018 Feb; 14(3):205-222. PubMed ID: 29140105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]